Sensorion SAS (ALSEN) AI Stock Analysis

• Market Cap: €109.42M
• Dividend Yield: N/A
• Average Volume (3M): 435.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: N/A
• EPS Growth: 55.02%
• Country: FR
• Employees: 63
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 300,661,220
• 10 Day Avg. Volume: 413,686
• 30 Day Avg. Volume: 435,987
• PEG Ratio: -0.02
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.00
• Price Target Upside: 455.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: €0.50 ▲(38.89%Upside)

Sensorion SAS's overall stock score reflects its financial challenges and valuation concerns, despite some positive technical indicators. The company's revenue growth and strong equity position are overshadowed by significant net losses and negative cash flows. Improvement in operational efficiency and profitability is crucial for future success.

Positive Factors

Clinical Trial Progress

Sensorion has completed enrollment for its Phase 2a study of SENS-401, indicating progress in their clinical trial efforts.

Drug Development

SENS-501 was safe and well-tolerated in all three children receiving the surgery and therapy.

Financial Stability

Sensorion ended the year with EUR77m in cash after two successful funding rounds, ensuring financial stability.

Negative Factors

Competitive Pressure

Competitor's encouraging updates and fast enrollment in trials raise the stakes for ALSEN's upcoming readout.

Drug Effectiveness Doubts

There are lingering uncertainties around SENS-401, with mean hearing loss similar between treated and control groups, creating doubts about its effectiveness.

Regulatory Delays

The expected IND submission for the GJB2-mediated hearing loss program has been delayed.

Sensorion SAS Business Overview & Revenue Model

Company Description

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

How the Company Makes Money

Sensorion SAS generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's main revenue streams include licensing agreements, collaborations with other pharmaceutical companies, and potentially, sales of approved therapies. Significant factors contributing to its earnings include successful clinical trials, regulatory approvals, and strategic partnerships that facilitate research and development or enhance market access. Sensorion may also benefit from grants and funding opportunities specific to innovation in biotechnology.

Sensorion SAS Financial Statement Overview

Summary

Sensorion SAS shows potential with revenue growth and a solid equity base. However, substantial net losses and negative cash flows present significant challenges. The company needs to focus on cost control and operational efficiency to improve profitability and cash flow stability.

Income Statement

Sensorion SAS has experienced revenue growth, but profitability remains a concern. While total revenue increased from the previous year, the company continues to operate at a significant net loss. The gross profit margin is positive, indicating effective revenue management, but negative EBIT and EBITDA margins reflect high operational costs. The consistent net loss indicates a need for improved cost management and revenue enhancement strategies.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio, suggesting financial stability. Stockholders' equity has improved significantly, indicating investor confidence and capital raising success. However, the persistent net losses continue to erode equity value. The equity ratio is healthy, reflecting a strong capital structure, but ongoing losses could pose risks if not addressed.

Cash Flow

Sensorion SAS exhibits a challenging cash flow position with negative operating and free cash flows. Despite generating significant financing cash flow, largely from equity raises, the company has been unable to generate positive free cash flow. The free cash flow to net income ratio remains negative, reflecting ongoing operational challenges. A focus on improving operating cash flow is essential for long-term financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.65M	5.70M	4.93M	4.26M	2.35M
Gross Profit	6.65M	3.79M	4.16M	3.75M	1.94M
EBITDA	-27.58M	-21.33M	-22.44M	-14.61M	-8.85M
Net Income	-25.97M	-22.06M	-23.21M	-15.14M	-8.98M
Balance Sheet
Total Assets	89.28M	46.50M	38.93M	59.02M	67.87M
Cash, Cash Equivalents and Short-Term Investments	76.98M	36.97M	26.20M	50.00M	62.17M
Total Debt	2.20M	2.87M	3.76M	3.99M	3.88M
Total Liabilities	17.14M	13.23M	17.06M	15.03M	9.52M
Stockholders Equity	72.14M	33.27M	21.87M	43.98M	58.35M
Cash Flow
Free Cash Flow	-22.45M	-21.94M	-22.92M	-11.81M	-5.48M
Operating Cash Flow	-21.33M	-21.07M	-21.41M	-10.77M	-5.31M
Investing Cash Flow	-11.13M	-381.06K	-1.54M	-1.07M	-164.93K
Financing Cash Flow	62.26M	32.20M	-820.68K	-326.07K	37.23M

Sensorion SAS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.36
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.35, and below the 200-day MA of 0.52, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.61 is Neutral, neither overbought nor oversold. The STOCH value of 68.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALSEN.

Sensorion SAS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.59B	0.18	-63.05%	2.16%	16.16%	0.65%
ALSEN	51 Neutral	€109.42M	―	-49.28%	―	―	55.02%
IPHYF	―	$203.81M	―	-160.99%	―	―	―
0QAV	―	€268.10M	―		―	―	―
0OCQ	―	€112.54M	―	-220.48%	―	―	―
6OP	―	€144.59M	3.65	86.78%	―	―	―
MAAT	39 Underperform	€72.17M	―		―	44.34%	-27.37%